Cargando…

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience

BACKGROUND: Immune checkpoint blockade (ICB) has improved outcomes for patients with microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) tumors. However, not all MSI-H/dMMR patients will exhibit the same ICB efficacy. Previous studies suggest that concomitant antibiotic use whil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serpas Higbie, Victoria, Rogers, Jane, Hwang, Hyunsoo, Qiao, Wei, Xiao, Lianchun, Dasari, Arvind, Mola-Rudd, Kerri, Morris, Van K, Wolff, Robert A, Raghav, Kanwal, Huey, Ryan, Parseghian, Christine, Willis, Jason, Kopetz, Scott, Overman, Michael J, Johnson, Benny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632313/ https://www.ncbi.nlm.nih.gov/pubmed/35946836 http://dx.doi.org/10.1093/oncolo/oyac162

Ejemplares similares

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
por: Leclerc, Julie, et al.
Publicado: (2021)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis
por: Fan, Shaoqing, et al.
Publicado: (2023)

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
por: Kang, Yoon-Jung, et al.
Publicado: (2022)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait
por: Huey, Ryan W., et al.
Publicado: (2021)

LDH‐A negatively regulates dMMR in colorectal cancer
por: Zhang, Yongjie, et al.
Publicado: (2021)

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
por: Wang, Jie, et al.
Publicado: (2021)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
por: Wang, Zhenghang, et al.
Publicado: (2022)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

An unusual case of microsatellite instability–high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
por: Han, Bogyeong, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
por: Zhang, Xuan, et al.
Publicado: (2022)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
por: Liao, Ying, et al.
Publicado: (2022)

Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
por: Yang, Renfang, et al.
Publicado: (2023)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review
por: Shen, Chan, et al.
Publicado: (2022)

Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report
por: Smith, Henry G., et al.
Publicado: (2023)

Prognostic value of Lynch syndrome, BRAF(V600E) , and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023)

Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7jm7jnnhc6hdto4d5urfu8apbj